GILD Gilead Sciences Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 40.28 P/E
- 10.52 P/S
- 10.32 P/B
- 1.817 EPS
- 50.50% Cash ROIC
- 3.94 Cash Ratio
- 0 / 0% Dividend
- 8.91M Avg. Vol.
- 790.12M Shares
- 113.5B Market Cap.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
4-traders (press release) - 2 hours ago
Gilead Announces Pivotal Phase 2 Results For Idelalisib In Refractory INHL - RTT News
4-traders (press release) - Dec 6, 2013
FDA approves Gilead's $1000-a-day hepatitis C pill - Chicago Tribune (blog)
SmallCap Network - 23 hours ago
Next iPhone News - 6 hours ago
MarketWatch - Dec 2, 2013
Seeking Alpha - Nov 26, 2013
Gilead Sciences Price Target Raised to $80.00 at Jefferies Group (GILD) - Ticker Report
Seeking Alpha - Nov 11, 2013
Seeking Alpha - Nov 24, 2013
4-traders (press release) - Dec 2, 2013
Stocks In Focus: Gilead Sciences, Inc.(NASDAQ:GILD), MannKind Corporation ... - Market News Call
SBWire (press release) - Dec 5, 2013